Efgartigimod PH20 is a combination subcutaneous (SC) infusion that contains efgartigimod alfa and hyaluronidase which may be used to improve muscle weakness in adults with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive.
The interim results presented by Argenx highlighted notable efficacy and tolerability of SC efgartigimod PH20. With manageable adverse events and consistent clinical improvements, it underscores the treatment's promising potential for gMG.
In the realm of treating gMG, the quest for safer and more effective therapeutic options is a perpetual endeavor. Amidst this pursuit, the interim results of the ADAPT-SC+ study shed ...
